Amphastar Pharma (AMPH) Misses Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil prices, producer inflation ease
- Oil pares losses after reports Houthis attacked Saudi Aramco refinery
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Amphastar Pharmaceuticals (AMPH) PT Lowered to $22 at Needham & Company
August 9, 2018 1:38 PM EDTNeedham & Company lowered its price target on Amphastar Pharmaceuticals (NASDAQ: AMPH) to $22.00 (from $24.00) while maintaining a Buy rating.
Analyst Serge Belanger remains positive as the recent approval of generic Isuprel, along with medroxyprogesterone and neostigmine will continue driving growth in... More
Amphastar Pharmaceuticals (AMPH) PT Lowered to $24 at Piper Jaffray
August 9, 2018 4:37 AM EDTPiper Jaffray lowered its price target on Amphastar Pharmaceuticals (NASDAQ: AMPH) to $24.00 (from $26.00) while maintaining a Overweight rating.
... More